Sanofi Aventis
Our Company
Sanofi-aventis U.S., based in Bridgewater, NJ, and employing 11,400 people across the country, is part of a leading global pharmaceutical company that discovers, develops, produces and markets innovative therapies that enhance people’s lives. Our extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines.
Sort by
Featured products
Glimepiride is a medium-to-long acting sulfonylurea anti-diabetic drug. It is marketed as Amaryl by Sanofi-Aventis and GLIMY by Dr.Reddy's Labs. Glimepiride is the first third-generation sulfonylurea, and is very potent.
| | |
Dacarbazine (da-KAR-ba-zeen) (brand names DTIC, DTIC-Dome; also known as DIC or Imidazole Carboxamide) is an antineoplastic chemotherapy drug used in the treatment of various cancers, among them malignant melanoma, Hodgkin lymphoma, sarcoma, and islet cell carcinoma of the pancreas.
|
Ofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.
|
Vigabatrin is an antiepileptic drug that inhibits the catabolism of gamma-aminobutyric acid (GABA) by irreversibly inhibiting GABA transaminase. It is an analog of GABA, but it is not a receptor agonist. It is sold under the brand name Sabril.
130.25 (USD)
100.19 (USD)
|